Table 1.
Baseline characteristics of patients in the internal, Duke, and SEERa datasets.
| Characteristics | Internal dataset (N=306) | Duke dataset (N=94) | SEER dataset (N=2760) | |
| Age (years), n (%) | ||||
|
|
>60 | 42 (13.7) | 14 (14.9) | 732 (26.5) |
|
|
≤40 | 60 (19.6) | 21 (22.3) | 548 (19.9) |
|
|
40-60 | 204 (66.7) | 59 (62.8) | 1480 (53.6) |
| Histological type, n (%) | ||||
|
|
Invasive ductal carcinoma | 290 (94.8) | 89 (94.7) | 2506 (90.8) |
|
|
Other | 16 (5.2) | 5 (5.3) | 254 (9.2) |
| ERb, n (%) | ||||
|
|
Negative | 124 (40.5) | 40 (42.6) | 686 (24.9) |
|
|
Positive | 182 (59.5) | 54 (57.4) | 2074 (75.1) |
| PRc, n (%) | ||||
|
|
Negative | 179 (58.5) | 52 (55.3) | 1093 (39.6) |
|
|
Positive | 127 (41.5) | 42 (44.7) | 1667 (60.4) |
| HER2d, n (%) | ||||
|
|
Negative | 212 (69.3) | 68 (72.3) | 1825 (66.1) |
|
|
Positive | 94 (30.7) | 26 (27.7) | 935 (33.9) |
| Molecular subtype, n (%) | ||||
|
|
HRe–/HER2– | 73 (23.9) | 29 (30.9) | 466 (16.9) |
|
|
HR–/HER2+ | 50 (16.3) | 11 (11.7) | 182 (6.6) |
|
|
HR+/HER2– | 139 (45.4) | 39 (41.5) | 1359 (49.2) |
|
|
HR+/HER2+ | 44 (14.4) | 15 (16.0) | 753 (27.3) |
| Tf, n (%) | ||||
|
|
1 | 36 (11.8) | 16 (17.0) | 449 (16.3) |
|
|
2 | 185 (60.5) | 58 (61.7) | 1458 (52.8) |
|
|
3 | 51 (16.7) | 17 (18.1) | 578 (20.9) |
|
|
4 | 34 (11.1) | 3 (3.2) | 275 (10.0) |
| Nf, n (%) | ||||
|
|
0 | 43 (14.1) | 41 (43.6) | 929 (33.7) |
|
|
1 | 142 (46.4) | 40 (42.6) | 1232 (44.6) |
|
|
2 | 61 (19.9) | 7 (7.4) | 343 (12.4) |
|
|
3 | 60 (19.6) | 6 (6.4) | 256 (9.3) |
| Mf, n (%) | ||||
|
|
0 | 295 (96.4) | 93 (98.9) | 2677 (97.0) |
|
|
1 | 11 (3.6) | 1 (1.1) | 83 (3.0) |
| S tatus , n (%) | ||||
|
|
0 | 252 (82.4) | 83 (88.3) | 2364 (85.7) |
|
|
1 | 54 (17.6) | 11 (11.7) | 396 (14.3) |
| Survival time, median (IQR) | 25.9 (17.2-36.3) | 50.2 (29.3-66.2) | 35.0 (15.5-64.0) | |
aSEER: Surveillance, Epidemiology, and End Results.
bER: estrogen receptor.
cPR: progesterone receptor.
dHER2: human epidermal growth factor receptor 2.
eHR: hormone receptor.
fTNM: tumor, node, metastasis.